Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study

Summary Aim:  To determine the rate of newly detected underlying disease in men receiving their first (index) phosphodiesterase type 5 inhibitor (PDE5i) prescription. Methods:  This non‐interventional, retrospective study used anonymised patient records from UK general practices identified from the...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical practice (Esher) 2011-07, Vol.65 (7), p.797-806
Main Authors: Kirby, M. G., Schnetzler, G., Zou, K.H., Symonds, T.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Case-Control Studies
Clinical medicine
Diabetes Complications - complications
Diabetes Complications - diagnosis
Drug therapy
Early Diagnosis
Epidemiology
Erectile dysfunction
Erectile Dysfunction - drug therapy
Erectile Dysfunction - etiology
General aspects
Humans
Hypercholesterolemia - complications
Hypercholesterolemia - diagnosis
Hypertension - complications
Hypertension - diagnosis
Hypogonadism - complications
Hypogonadism - diagnosis
Incidental Findings
Inhibitor drugs
Male
Medical sciences
Mens health
Middle Aged
Phosphodiesterase 5 Inhibitors - therapeutic use
Public health. Hygiene
Public health. Hygiene-occupational medicine
Retrospective Studies
Sexual disorders
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Aim:  To determine the rate of newly detected underlying disease in men receiving their first (index) phosphodiesterase type 5 inhibitor (PDE5i) prescription. Methods:  This non‐interventional, retrospective study used anonymised patient records from UK general practices identified from the THIN database. Records of men aged ≥ 18 years, who received an index PDE5i prescription between January 1999 and June 2008 and with a continuous medical history (≥ 60 months) before the index prescription were included. Primary end‐points were the prevalence of underlying disease prior to the index prescription and to establish the detection rate, defined as cumulative incidence of such a diagnosis in the 3 months following the index prescription. Assessments included comparison with age‐matched controls, comparison with identical time periods immediately before and 1 year after, index prescription, and changes over time during the study period. Descriptive statistics, analysis of proportions and multivariate logistic regression analysis were used. Results:  Among the 24,708 patients receiving a PDE5i, the prevalence of any underlying diagnosis before the index prescription was 70.23%; prevalence of vasculogenic disease was highest (48.20%). The detection rate of any underlying disease was 11.53%, and again highest for vasculogenic disease (4.07%). Compared with an age‐matched control population, the additional detection rate of an unknown underlying disease at PDE5i prescription was 45 for hypertension, 61 for hypercholesterolaemia, 38 for diabetes and 5 for hypogonadism per 10,000 men. Conclusion:  Only a minority of men with erectile dysfunction have a previously undiagnosed important underlying disease that is uncovered at the time of an initial PDE5i prescription by a GP.
ISSN:1368-5031
1742-1241
DOI:10.1111/j.1742-1241.2011.02693.x